|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.22 EUR | +4.99% |
|
+10.75% | +11.98% |
| Dec. 10 | Medincell Narrows Operating Loss in First Half |  |
| Dec. 10 | MedinCell Says Partner Filed US FDA Application for Once-monthly Schizophrenia Treatment | MT |
Projected Income Statement: MedinCell S.A.
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.186 | 4.091 | 9.889 | 9.032 | 25.42 | 31.17 | 46.25 | 93.7 |
| Change | - | -50.02% | 141.73% | -8.67% | 181.43% | 22.63% | 48.36% | 102.61% |
| EBITDA 1 | - | -22.3 | -22.36 | -19.26 | -8.85 | -1.087 | 22.5 | 62.04 |
| Change | - | - | -0.29% | 13.87% | 54.05% | 87.71% | 2,169.86% | 175.69% |
| EBIT 1 | -15.37 | -23.81 | -24.02 | -20.94 | -10.76 | -4.704 | 15.46 | 85.98 |
| Change | - | -54.95% | -0.89% | 12.84% | 48.61% | 56.29% | 428.71% | 456.13% |
| Interest Paid 1 | - | -1.754 | -7.964 | -3.973 | -7.438 | -5.5 | -3.191 | -4.265 |
| Earnings before Tax (EBT) 1 | - | -24.81 | -32.01 | -24.95 | -18.28 | -23.33 | -16.5 | 78.5 |
| Change | - | - | -29.04% | 22.06% | 26.74% | -27.66% | 29.28% | 575.76% |
| Net income 1 | -19.02 | -24.81 | -29.5 | -25.04 | -18.44 | -12.96 | 1.2 | 57.83 |
| Change | - | -30.42% | -18.91% | 15.12% | 26.36% | 29.72% | 109.26% | 4,719.44% |
| Announcement Date | 6/16/21 | 6/14/22 | 6/26/23 | 6/10/24 | 6/17/25 | - | - | - |
1EUR in Million
Estimates
Forecast Balance Sheet: MedinCell S.A.
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 22.9 | 48.2 | 42.3 | -7.3 | 15.9 | 27.5 | -39.3 |
| Change | - | - | 110.48% | -12.24% | -117.26% | 317.93% | 72.96% | -242.91% |
| Announcement Date | 6/16/21 | 6/14/22 | 6/26/23 | 6/10/24 | 6/17/25 | - | - | - |
1EUR in Million
Estimates
Cash Flow Forecast: MedinCell S.A.
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| CAPEX 1 | 1.974 | 1.027 | 1.191 | 1.66 | 1.002 | 1.593 | 2.49 |
| Change | - | -47.97% | 15.97% | 39.38% | -39.62% | 58.93% | 56.3% |
| Free Cash Flow (FCF) 1 | -22.98 | -22.03 | -13.11 | 17.8 | -25.45 | -4.2 | 56.85 |
| Change | - | 4.15% | 40.48% | 235.78% | -242.94% | 83.5% | 1,453.57% |
| Announcement Date | 6/14/22 | 6/26/23 | 6/10/24 | 6/17/25 | - | - | - |
1EUR in Million
Estimates
Forecast Financial Ratios: MedinCell S.A.
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | -545% | -226.11% | -213.22% | -34.82% | -3.49% | 48.66% | 66.21% |
| EBIT Margin (%) | -187.74% | -582.06% | -242.95% | -231.84% | -42.34% | -15.09% | 33.43% | 91.77% |
| EBT Margin (%) | - | -606.36% | -323.69% | -276.24% | -71.91% | -74.85% | -35.68% | 83.78% |
| Net margin (%) | -232.35% | -606.36% | -298.29% | -277.21% | -72.54% | -41.57% | 2.59% | 61.72% |
| FCF margin (%) | - | -561.84% | -222.79% | -145.18% | 70.05% | -81.64% | -9.08% | 60.67% |
| FCF / Net Income (%) | - | 92.66% | 74.69% | 52.37% | -96.57% | 196.41% | -350% | 98.3% |
Profitability | ||||||||
| ROA | - | - | - | - | - | - | 7% | 28.7% |
| ROE | - | - | - | - | - | 170.82% | 101.46% | 80.3% |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | -1.03x | -2.15x | -2.2x | - | -14.59x | 1.22x | - |
| Debt / Free cash flow | - | -1x | -2.19x | -3.23x | - | -0.62x | -6.54x | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | 48.25% | 10.39% | 13.19% | 6.53% | 3.22% | 3.44% | 2.66% |
| CAPEX / EBITDA (%) | - | -8.85% | -4.59% | -6.18% | -18.76% | -92.19% | 7.08% | 4.01% |
| CAPEX / FCF (%) | - | -8.59% | -4.66% | -9.08% | 9.32% | -3.94% | -37.93% | 4.38% |
Items per share | ||||||||
| Cash flow per share 1 | - | - | -0.83 | -0.4195 | 0.6568 | -0.7 | -0.1 | 4.3 |
| Change | - | - | - | 49.46% | 256.57% | -206.57% | 85.71% | 4,400% |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | -0.5325 | -1.673 | -1.436 | -0.5523 | 0.01 | 1.22 | 3.89 |
| Change | - | - | -214.18% | 14.14% | 61.55% | 101.81% | 12,100% | 218.85% |
| EPS 1 | -0.86 | -1 | -1.27 | -0.88 | -0.62 | -0.396 | 0.09 | 1.65 |
| Change | - | -16.28% | -27% | 30.71% | 29.55% | 36.13% | 122.73% | 1,733.33% |
| Nbr of stocks (in thousands) | 24,581 | 25,121 | 25,101 | 28,749 | 33,066 | 33,103 | 33,103 | 33,103 |
| Announcement Date | 6/16/21 | 6/14/22 | 6/26/23 | 6/10/24 | 6/17/25 | - | - | - |
1EUR
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E ratio | -71.3x | 314x |
| PBR | 2,822x | 23.1x |
| EV / Sales | 30.5x | 20.8x |
| Yield | - | - |
More valuation ratios
* Estimated data
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
28.22EUR
Average target price
36.16EUR
Spread / Average Target
+28.14%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MEDCL Stock
- Financials MedinCell S.A.
Select your edition
All financial news and data tailored to specific country editions
